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ScienceDirectThe gold standard cell therapy for repair of articular cartilage
defects is autologous chondrocyte implantation, with good
outcomes long-term. Mesenchymal stromal/stem cells (MSCs)
from bone marrow or connective tissues such as fat are being
pursued as alternatives for cartilage repair, and are trialled via
intra-articular administration in patients with knee
osteoarthritis. Early-phase clinical studies concur on safety and
provide some promising insight into efficacy, but the
mechanism of action remains unclear. Recent studies implicate
extracellular vesicles as important mediators of MSC action,
offering exciting therapeutic prospects. Our increasing
understanding of the mechanisms underlying intrinsic articular
cartilage maintenance and repair fosters hope that novel/
repurposed therapeutics could elicit repair through activation
of endogenous stem/progenitor cells to maintain healthy joints
and prevent osteoarthritis.
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Introduction
Osteoarthritis (OA) is a common degenerative joint dis-
ease, characterised by progressive cartilage breakdown,
subchondral bone sclerosis and aberrant bone outgrowths
(osteophytes). Traumatic joint lesions increase the risk of
OA. Advances in the regenerative treatment of early
cartilage lesions could help to prevent OA. This review
discusses cell-based approaches for the repair of cartilage
lesions and the treatment of OA (Figure 1).
Cartilage repair
A commonly performed surgical procedure is microfrac-
ture, a marrow stimulation technique that allows commu-
nication between the joint space and subchondral boneCurrent Opinion in Pharmacology 2018, 40:74–80 marrow to release mesenchymal stromal/stem cells
(MSCs) from the marrow that form a repair tissue. How-
ever, particularly in defects larger than 2 cm2, the repair
tissue with microfracture frequently undergoes degener-
ation over time with the formation of scar-like fibrous
tissue or even replacement with bone [1].
Autologous chondrocyte implantation (ACI) was first
described in 1994 by Brittberg and colleagues, who
reported symptomatic relief in 14 out of 16 patients with
lesions of the femoral condyle at 2 years follow-up [2]. A
cartilage biopsy is obtained from a healthy area of the
patient’s articular cartilage, chondrocytes are isolated and
expanded in culture, and are implanted in the cartilage
defect either in suspension under a periosteal flap or
synthetic membranes, or in three-dimensional matrices
[3]. Clinical trials have confirmed the good clinical out-
come of ACI. In 118 patients at 12 and 18 months follow-
ing either ACI or microfracture, clinical outcome was
similar in both groups but ACI was associated with
increased structural repair [4]. At 5 years, clinical outcomes
were again comparable [5]. However, ACI was more
effective in a subgroup of patients who had undergone
the procedures close to presentation of symptoms [6].
Results from up to 20 years follow-up have demonstrated
that ACI is an effective and durable solution for the
treatment of large joint surface lesions of the knee [7,8].
However, variability in structural outcome after ACI has
been reported, with some patients showing repair tissue
consisting of disorganised fibrocartilage [9]. Chondrocytes
dedifferentiate during culture-expansion to a fibroblast-
like phenotype and lose their capacity to form stable
hyaline cartilage in vivo [10], which may underpin the
variability in structural outcome. The use of chondrocytes
expanded under conditions that preserve their cartilage-
forming potency may enhance joint surface regeneration
with the formation of hyaline-like cartilage repair tissue
[11]. Of interest, chondrocytes derived from the nasal
septum, with known capacity to generate hyaline-like
cartilage, have been successfully used for knee cartilage
defect repair in ten patients [12], but large controlled
trials are warranted to assess efficacy.
MSCs are easy to grow in culture and have chondrogenic
ability, and are therefore considered an alternative cell
source for cartilage repair. MSCs have been isolated from
bone marrow [13,14], and most connective tissues includ-
ing periosteum [15,16], synovium [17,18], and adipose
tissue [19]. Numerous preclinical studies have supportedwww.sciencedirect.com
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Regenerative therapeutic strategies for cartilage defects and osteoarthritis. Exogenous cell-based therapy entails delivery of autologous or
allogeneic cells such as chondrocytes or mesenchymal stromal/stem cells (MSCs), or extracellular vesicles (EVs), either in suspension or seeded in
a biomaterial. Alternatively, endogenous chondroprogenitors, which reside in synovium (S), bone marrow (BM) and cartilage itself, could be
targeted with pharmaceutical drugs or bioactive scaffolds to trigger or enhance intrinsic repair.the use of MSCs in joint resurfacing [20], and studies in
humans revealed a variable structural outcome, ranging
from hyaline-like cartilage to fibrous tissue [21]. Notably,
autologous bone marrow MSCs were shown to be non-
inferior to chondrocytes in clinical outcomes at 24 months
in an ACI-like procedure [22], although longer-term
follow-up and more robust assessment of structural out-
come are needed to draw definitive conclusions.
An important consideration is the tissue source of MSCs
for cartilage repair, and whether MSCs from non-joint
environments such as the stromal vascular fraction of
visceral fat would be comparable to MSCs derived from
joint tissues. MSCs from bone marrow appear to have high
propensity to undergo chondrocyte hypertrophy and bone
formation [23,24] and thus may not be ideal for the repair
of articular cartilage. Superiority of MSCs from synovium
for cartilage formation in vitro when compared with MSCs
from other tissues including bone marrow and periosteum
has been reported [25]. The differences in potency could
be related to MSC ontogeny and distinctive molecular
programmes of embryonic formation of the native tissues
from which the MSCs are obtained. Lineage tracing
studies in mice have demonstrated that articular cartilage
and synovium have a common developmental origin from
the Gdf5-expressing cells of the embryonic jointwww.sciencedirect.com interzone. Gdf5-traced MSCs resident in the adult knee
were found to display joint progenitor activity and ability
to repair articular cartilage [26,27]. Promising data
using synovium-derived MSCs have been reported in
preclinical and clinical studies [28,29,30].
Notably, chondroprogenitors derived from the surface
zone of articular cartilage using differential adhesion to
fibronectin, showed ability to maintain chondrogenic
potency upon extensive expansion [31], and formed a
cartilage-like repair tissue in a chondral defect in a goat
model [32]. Human studies are awaited.
Interventions consisting of implantation of stem/progen-
itor cells seeded in smart biomaterials, with the addition
of cartilage-promoting growth factors, are also being pur-
sued to support adequate repair [33], but such combina-
tions render the path to clinical application complex.
Osteoarthritis
Intra-articular injection of bone marrow MSCs in goats, in
which the medial meniscus was excised and the anterior
cruciate ligament was resected, resulted in regeneration
of the medial meniscus and decreased development of
secondary OA compared with untreated animals [34].
This and many other subsequent preclinical studiesCurrent Opinion in Pharmacology 2018, 40:74–80
76 Musculoskeletal[20] have constituted the foundation for cultured MSCs
being trialled as therapy in patients with OA, mostly in
the knee. Recent systematic reviews of phase I/II clinical
trials (not always controlled or blind) concluded that
MSCs, obtained most commonly from bone marrow or
adipose tissue and injected intra-articularly into the knee,
are overall safe and well tolerated. Furthermore, MSCs
can improve pain and function of the knee joint, with
scattered histological data suggesting formation of hya-
line-like cartilage repair tissue [35,36]. A meta-analysis of
11 small trials of MSC therapy for knee OA, including a
total of 582 knee OA patients, reported improvements
across a range of clinical outcome measures [37]. How-
ever, the efficacy of these therapies cannot be determined
until large randomised controlled trials are carried out.
While most studies have used autologous cells, allogeneic
MSCs appear to have an acceptable safety profile
[38,39]. Their use would be advantageous over autolo-
gous procedures by allowing manufacturing of large
batches of off-the-shelf MSC products, which would
enhance consistency and decrease the costs of cell
therapy.
To circumvent the hurdles of culture expansion such as
costs and variability, fresh bone marrow aspirate concen-
trate would provide a readily available autologous cellular
product for intra-articular delivery, and has been shown to
be safe in 25 patients with knee OA [40]. Protocols for
digestion of fresh bone marrow aspirate have been devel-
oped for enrichment of clinical grade CD271+ MSCs for
orthopaedic applications [41], but potency of the cellular
product and clinical feasibility need to be determined.
In summary, cell therapy has proven safe but large
controlled studies are needed to confirm whether cell
therapy can improve pain and induce structural benefit in
OA. Standardisation of cell product manufacturing
(including potency assessment), frequency and method
of delivery, and definition of target patient populations
through stratification will be necessary to determine
efficacy and allow meaningful comparisons of clinical
study outcomes.
MSC-derived extracellular vesicles
The mechanism of action of MSC therapy remains
unclear. Evidence that injected MSCs contribute directly
to joint tissue repair is limited. MSCs could modulate the
joint environment and mediate intrinsic tissue repair via
paracrine signals. Recent studies have reported that
MSC-derived extracellular vesicles (EVs) can promote
cartilage repair and protect against OA-induced cartilage
degeneration [42,43,44,45]. EVs are small, membrane-
enclosed particles that are released from cells either
through budding from the cell membrane (microvesicles)
or through fusion of endosomal multivesicular bodies
with the plasma membrane (exosomes). They contain
biologically active signalling molecules and can bind toCurrent Opinion in Pharmacology 2018, 40:74–80 target cells via ligand-receptor interactions. They can
activate intracellular signalling from the plasma mem-
brane or can be internalised resulting in intracellular
delivery of their cargo.
Single intra-articular injections of mouse bone marrow
MSC-derived exosomes or microvesicles were both simi-
larly effective in protecting against the development of
collagenase-induced OA in mice compared to injection of
whole MSCs [42], suggesting that EVs may be major
paracrine factors mediating the protective effects of
MSCs. Weekly intra-articular injections of exosomes from
MSCs generated from human embryonic stem cells
resulted in improved repair of critical-sized osteochondral
defects in the femoral groove in immunocompetent rats
[43,44]. Rat chondrocytes in vitro internalised the exo-
somes and increased their proliferation and migration rate
which was at least in part mediated via rapid activation of
AKT and ERK through CD73-mediated adenosine sig-
nalling [44].
Other recent studies showed that intra-articular adminis-
tration of exosomes derived from cultured rat synovial
MSCs partly prevented cartilage damage in a trauma-
induced rat OA model, and this OA protective effect was
enhanced with exosomes from miR-140-5p overexpres-
sing synovial MSCs [45]. In vitro experiments showed
synovial MSC-derived exosomes to contain high levels of
Wnt5a/b, which upregulated Yap in exosome-treated
chondrocytes to promote proliferation and migration
but downregulated synthesis of cartilage matrix proteins
[45]. The latter was overcome by loading exosomes with
miR-140-5p [45], a pro-chondrogenic miRNA important
for maintaining cartilage homeostasis [46,47], showing
amenability of the EV cargo to be modified for optimal
targeted delivery to enhance efficacy.
Biodistribution of EVs following intra-articular delivery is
not known. Although EVs can attach to and penetrate the
cartilage, at least in an inflammatory arthritis model
[48], EVs may be subject to rapid clearance from the
joint space. Encapsulating EVs in a suitable biomaterial to
prevent rapid clearance and achieve sustained effects
could facilitate clinical translation, and is being explored
for cartilage repair [49]. Similar to cell therapies, it will be
crucial for therapeutic use of EVs to ensure high-quality,
standardised EV production and purification methods
compatible with clinical application.
Targeting joint-resident MSCs
Since MSC populations can be derived from multiple
tissues in the joint, including synovium [18], infrapatellar
fat pad [50], synovial fluid [51,52] and the cartilage itself
[31], why joint-resident MSCs would fail to repair dam-
aged cartilage remains unclear. Their repair capacity may
be progressively impaired in ageing, and a reduction in
MSC populations and their proliferative andwww.sciencedirect.com
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An increased number of MSCs in the synovial fluid [54]
and bone marrow lesions of OA patients [55] suggests
that an MSC-mediated attempt to repair would occur
albeit ineffectively, which may be due to a hostile envi-
ronment or impaired MSC regenerative function or senes-
cence [55,56]. An in-depth understanding of the role of
MSCs in joint homeostasis, remodelling, repair and OA
pathogenesis is therefore needed.
Particularly at early disease stages, the prospect to support
MSCs in their function to maintain joints as healthy as
possible while preventing progression of damage is excit-
ing. The use of bioactive scaffolds or therapeutics that
elicit an effective tissue repair response through activa-
tion and mobilisation of endogenous stem/progenitor
cells, without the need to administer exogenous cells,
would be easier to implement clinically and likely to
encounter fewer regulatory hurdles. A study showing that
intra-articular injection of kartogenin protected against
OA development in mice, possibly via modulating endog-
enous stem cells to promote repair [57], provided insights
regarding novel cell-free regenerative therapy for OA.
The lack of an exclusive marker for MSCs in joint tissues
has hampered studies of joint-resident MSCs [58].
Recently, genetic tools allowing lineage tracing in mice
have elucidated the ontogeny of MSCs in adult tissues
while providing means to locate and monitor these cells in
health and disease. It has thus become clear that MSCs in
bone marrow in adult life primarily support and regulate
haematopoiesis through interactions with haematopoietic
stem cells [59] and replenish osteoblasts [60]. In parallel,
stem/progenitor cell kinetics in joint development,
homeostasis and repair are being unravelled, providing
previously unappreciated clues for cartilage regeneration/
repair. Three independent studies have demonstrated
that Prg4-traced cells in the joint have properties of
progenitor cells during postnatal life [27,61,62], but
their natural healing potential remains uncertain. Two
independent studies have shown that the Prg4-lineage,
and the Gdf5-lineage deriving from the embryonic joint
interzone, which are at least partly overlapping in the
adult joint, contribute chondroprogenitors to cartilage
repair in mice [26,27]. Such lineage cells are present
in both the synovium and the superficial zone of cartilage,
and the question as to where the progenitors are located
remains to be addressed. Contribution from the superfi-
cial zone cannot be excluded, since superficial zone cells
are able to migrate to the site of injury in cartilage
explants [63]. However, the absence of detectable pro-
liferation of those lineage cells in cartilage and, instead,
their considerable expansion to underpin the synovial
lining hyperplasia following injury [26,27], have
seeded the idea that the chondroprogenitors that contrib-
ute to cartilage repair would originate from the synovium.
Of interest, inactivation of the transcriptional co-factorwww.sciencedirect.com Yap in the Gdf5 lineage abrogated the synovial lining
hyperplasia and reduced the contribution of Gdf5-traced
cells to cartilage repair, but cartilage repair could still take
place [26], suggesting a simultaneous and/or compen-
satory recruitment of chondroprogenitors from other
lineages, which may include the Leptin receptor lineage
in bone marrow [64].
MSCs have also been found in the synovial fluid, and
comparative gene profiling showed the MSCs from syno-
vial fluid to be closer to MSCs from synovium than to
MSCs from bone marrow, suggesting that they might
originate in the synovium [54]. Whether MSCs percolate
in the fluid to become available at the site of injury is yet to
be proven.
Conclusions
Cell-based therapies are increasingly becoming available
for the repair of joint surface lesions and OA. A one-fits-all
solution is unlikely and instead the type of regenerative
intervention will depend on targeting the right patient
through personalised medicine and OA stratification.
While progress in our understanding of mechanism of
action has been made and several clinical trials are ongo-
ing, the journey towards routine regenerative medicine
applications for OA patients in clinic remains complex.
Together with the trial-and-error clinical approaches,
evidence-based refinements will be implemented as
guided by our increasing knowledge of the regenerative
biology of the synovial joints.
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